ASX:EX1 Exopharm (EX1) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free EX1 Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Exopharm alerts: Email Address Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About ExopharmExopharm Limited develops transformative medicines based upon exosomes or extracellular vesicles (EVs) in Australia. The company's technology includes LOAD technology platform that enables loading of active pharmaceutical ingredient (API) into exosomes; Ligand-based Exosome Affinity Purification (LEAP) technology that solves the critical bottleneck of exosome isolation and purification; MASTER CELL BANK to manufacture clinical-grade engineered exosomes; EVPS technology platform that allows specific molecules to be attached to the surface of exosomes to target them to selected tissues, organs, or cell types; EXORIA, a novel and proprietary dye that tags invisible exosomes to enhance tracking in experimental studies and laboratory analysis; and FORMULATION H to enable the stable storage and transport of exosome medicines. Exopharm Limited has research collaboration agreements with Astellas Institute for Regenerative Medicine. The company was incorporated in 2013 and is based in Camberwell, Australia.Read More Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 EX1 Stock News HeadlinesNovember 20, 2023 | bbc.comEX1 - Weather warnings issuedNovember 18, 2023 | finance.yahoo.comExopharm Limited (EX1.XA)April 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.August 30, 2023 | finance.yahoo.comExopharm Full Year 2023 Earnings: AU$0.036 loss per share (vs AU$0.064 loss in FY 2022)May 22, 2023 | finance.yahoo.comOne Exopharm Insider Raised Their Stake In The Previous YearDecember 2, 2022 | finance.yahoo.comExopharm Limited (ASX:EX1) insider upped their holding by 15% earlier this yearAugust 27, 2022 | finance.yahoo.comExopharm Limited (EX1.AX)June 22, 2022 | finance.yahoo.comExopharm Limited (ASX:EX1) up 14%, but insiders are still down 49% after purchasing AU$895k of stock last yearApril 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.May 11, 2022 | finance.yahoo.comIs Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?See More Headlines Receive EX1 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exopharm and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:EX1 CUSIPN/A CIKN/A Webwww.exopharm.com Phone61 3 9111 0026FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-121.54% Return on Assets-51.37% Debt Debt-to-Equity Ratio37.16 Current Ratio7.82 Quick Ratio2.03 Sales & Book Value Annual Sales$1.18 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.39 Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares439,420,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.26 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Ian E. Dixon M.A.I.C.D.M.B.A., MBA, Ph.D., Founder, Technology Co-Founder, CEO MD & DirectorDr. Gregor Lichtfuss M.Sc.Co-Founder & Business Services ManagerMr. Johannes MuhlSenior Vice President of FinanceMr. David James Franks BEc (Age 54)C.A., F Fin, J.P., Company Secretary Key Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersClarke BarlowSold 10,000,000 sharesTotal: $110,000.00 ($0.01/share)Jason WatsonSold 380,000 sharesTotal: $3,800.00 ($0.01/share) This page (ASX:EX1) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exopharm Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
